247 related articles for article (PubMed ID: 26240233)
1. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.
Wright AA; Cronin A; Milne DE; Bookman MA; Burger RA; Cohn DE; Cristea MC; Griggs JJ; Keating NL; Levenback CF; Mantia-Smaldone G; Matulonis UA; Meyer LA; Niland JC; Weeks JC; O'Malley DM
J Clin Oncol; 2015 Sep; 33(26):2841-7. PubMed ID: 26240233
[TBL] [Abstract][Full Text] [Related]
2. Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
Miller EM; Tymon-Rosario J; Xie X; Xue X; Gressel GM; Miller DT; Kuo DY; Nevadunsky NS
Gynecol Oncol; 2017 Oct; 147(1):36-40. PubMed ID: 28751119
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
[TBL] [Abstract][Full Text] [Related]
4. Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registry data.
Adambekov S; Lopa S; Edwards RP; Lemon L; Wang S; Taylor SE; Orr B; Linkov F
Cancer Med; 2020 Oct; 9(20):7388-7397. PubMed ID: 32813321
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
6. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer.
Fairfield KM; Murray K; LaChance JA; Wierman HR; Earle CC; Trimble EL; Warren JL
Gynecol Oncol; 2014 Sep; 134(3):473-7. PubMed ID: 24952367
[TBL] [Abstract][Full Text] [Related]
8. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer.
Yen MS; Twu NF; Lai CR; Horng HC; Chao KC; Juang CM
Gynecol Oncol; 2009 Sep; 114(3):415-9. PubMed ID: 19577277
[TBL] [Abstract][Full Text] [Related]
9. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
10. Toxicities, complications, and clinical encounters during intraperitoneal chemotherapy in 17 women with ovarian cancer.
Sun V; Otis-Green S; Morgan R; Wakabayashi M; Hakim A; Callado ME; Yang E; Ferrell B; Grant M
Eur J Oncol Nurs; 2013 Jun; 17(3):375-80. PubMed ID: 23153453
[TBL] [Abstract][Full Text] [Related]
11. ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2008 Jan; 111(1):249. PubMed ID: 18165421
[TBL] [Abstract][Full Text] [Related]
12. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal chemotherapy for advanced epithelial ovarian malignancy: lessons learned.
Bunting M; Chan W; Brand A; Blomfield P
Aust N Z J Obstet Gynaecol; 2009 Dec; 49(6):667-71. PubMed ID: 20070720
[TBL] [Abstract][Full Text] [Related]
14. National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer.
Trimble EL; Christian MC
Int J Gynecol Cancer; 2008; 18 Suppl 1():26-8. PubMed ID: 18336395
[TBL] [Abstract][Full Text] [Related]
15. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
Nica A; Covens A; Parra-Herran C; May T
Gynecol Oncol; 2020 Sep; 158(3):622-630. PubMed ID: 32561124
[TBL] [Abstract][Full Text] [Related]
16. Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.
Battelli C; Campo M; Buss MK; Awtrey CS; Konstantinopoulos PA
Chemotherapy; 2013; 59(4):251-9. PubMed ID: 24457572
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.
Rao G; Crispens M; Rothenberg ML
J Clin Oncol; 2007 Jul; 25(20):2867-72. PubMed ID: 17617517
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
[TBL] [Abstract][Full Text] [Related]
20. [Intraperitoneal chemotherapy in first-line combination treatment for advanced ovarian cancer].
Massard C; Lhommé C; Pautier P
Bull Cancer; 2007 Apr; 94(4):398-404. PubMed ID: 17449443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]